Amprion, Inc.
1 known investors
Find your way into Amprion, Inc.
Amprion offers SAAmplify-αSYN, a clinically validated diagnostic test that detects misfolded (pathological) α-synuclein in cerebrospinal fluid to aid diagnosis of neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and Alzheimer's. The seed amplification assay is aimed at physicians and researchers, providing biology-based evidence to support diagnosis of mixed neurodegenerative pathologies.
Investors · 1
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $685.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2019 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $217.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $223.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2013 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $165.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Amprion, Inc. do?
- Amprion offers SAAmplify-αSYN, a clinically validated diagnostic test that detects misfolded (pathological) α-synuclein in cerebrospinal fluid to aid diagnosis of neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and Alzheimer's. The seed amplification assay is aimed at physicians and researchers, providing biology-based evidence to support diagnosis of mixed neurodegenerative pathologies.
- Who are Amprion, Inc.'s investors?
- Amprion, Inc.'s investors include Decathlon Capital Partners.